A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered ALS-008176 Regimens in Adult Subjects Hospitalized with Respiratory Syncytial Virus
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Lumicitabine (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Janssen Pharmaceutical KK
- 04 Dec 2017 Planned number of patients changed from 216 to 126.
- 06 Nov 2017 Planned End Date changed from 7 Jun 2018 to 27 Feb 2019.
- 14 Aug 2017 Planned End Date changed from 30 Apr 2018 to 7 Jun 2018.